IMARC Group's report titled “Duchenne Muscular Dystrophy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The global duchenne muscular dystrophy drugs market size reached US$ 2.04 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.00 Billion by 2028, exhibiting a growth rate (CAGR) of 11.41% during 2023-2028.

Duchenne muscular dystrophy (DMD) drugs are used to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that mainly affects the male population and rarely females. The symptoms of this disease include difficulty walking, standing, and sitting, and speech difficulties, which can result in progressive weakness and loss, also called as atrophy, in the skeletal and heart muscles. The Duchenne muscular dystrophy drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Consequently, most of the drugs for the treatment of DMD are dystrophin-based.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/duchenne-muscular-dystrophy-drugs-market/requestsample

Duchenne Muscular Dystrophy Drugs Market Trends and Drivers:

The growing number of new product approvals and launches by the key manufacturers, on account of the increasing incidences of this disorder among consumers, is primarily driving the Duchenne muscular dystrophy drugs market. Furthermore, the rising clinical trials and the presence of a strong pipeline of items are also augmenting the market growth. Apart from this, the introduction of mutation-specific therapies, owing to continuous innovations in diagnostics, is positively influencing the global market. Moreover, extensive research and development (R&D) activities focusing on the proper detection and treatment of DMD for underserved categories, such as infants, females, and non-ambulant patients, are further bolstering the market growth. Besides this, the launch of favorable government initiatives providing good reimbursement policies and promoting target-specific treatments is acting as another significant growth-inducing factor. Additionally, rising urbanization levels and continuous improvements in medical infrastructure are also catalyzing the global market. In addition to this, the emerging product premiumization trend and inflating disposable incomes of the masses are expected to drive the Duchenne muscular dystrophy drugs market in the coming years.

Report Segmentation:

The report has segmented the market into the following categories:

Product Type Insights:

• Corticosteroids
  • Prednisolone
  • Prednisone
  • Deflazacort
• Pain Management Drugs

Therapeutic Approach Insights:

• Mutation Suppression
• Exon Skipping 
• Steroid Therapy

End User Insights:

• Hospitals
• Clinics
• Home Care Settings

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Competitive Landscape with Key Player:

• Coromandel
•  

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA

Follow us on Twitter: @imarcglobal